Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
AnaptysBio, Inc. has divested First Tracks Biotherapeutics, a healthcare services other business in California, for $0.001. First Tracks Biotherapeutics operates in healthcare services other, supporting activities tied to biotherapeutics and related healthcare services in CA. The divestiture acquisition is part of healthcare M&A involving CA acquisitions and healthcare deals CA. The separation and distribution framework includes asset transfers, contract handling, and indemnification provisions, with no binding agreement in the draft form and an announced status pending execution by all parties.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026